Hormone-free option
Safety focused
Women’s Health Clinic FAQ
Are intimate polynucleotides safe for cancer survivors?
Intimate polynucleotides are non-hormonal biostimulatory treatments used in some clinics for vulvovaginal tissue quality. The important first step is confirming the symptom cause, not choosing an injectable by name.
Direct answer
Intimate polynucleotides are hormone-free, but cancer survivors should still have an individual clinical review before treatment. A non-hormonal injectable is not automatically suitable after breast, gynaecological, anal or colorectal cancer treatment. The safest approach is to confirm the cause of symptoms, check infection, bleeding, allergy and healing risks, and involve oncology or a relevant specialist where needed. Established GSM care and non-hormonal options should be discussed alongside polynucleotides, not bypassed.
Your clinician should review symptoms, medical history, allergies, medicines, cancer history where relevant, alternatives, expected benefits, limitations and aftercare before deciding whether treatment fits.
Educational only. Suitability must be confirmed after consultation and assessment. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether intimate polynucleotides are suitable.
Polynucleotides at a glance
Non-hormonal biostimulation
Composition
Polynucleotides (such as NewGyn) are highly purified DNA fragments derived from trout or salmon sperm .
Mechanism
They stimulate dermal fibroblasts to produce new collagen and elastin, deeply hydrating and restoring tissue elasticity and thickness .
Primary Indications
potentially useful for treating vaginal dryness, dyspareunia (painful intercourse), itching, and tissue atrophy caused by chemoradiotherapy or aromatase inhibitors .
Hormone Status
They are 100% non-hormonal, making them a safe tissue-repair alternative to ooooestrogen creams for high-risk oncology patients .
Important safety note
Safety Profile: Polynucleotides are formulated as CE-marked Class III medical devices, meaning they lack direct pharmacological activity and possess a strong, established safety profile .
Allergy
Evidence
Aftercare
Alternatives
Detailed answer
Cancer history and specialist input
Discuss GSM symptoms after cancer treatment with appropriate specialist advice before considering a hormone-free injectable.
Not ooestrogen, not automatic
Hormone-free status may be useful, but it does not remove the need for diagnosis, allergy screening, infection checks or cancer-history review.
Evidence
Symptoms
Alternatives
What it means
Up to 85% of anal squamous cell carcinoma survivors and a massive portion of breast cancer survivors suffer from debilitating GSM due to iatrogenic menopause .
Why symptoms matter
Standard treatments like local oooestrogen carry uncertainties regarding breast cancer recurrence risk, leaving many survivors undertreated and avoiding intimacy due to severe pain .
Evidence limits
Evidence is encouraging in selected areas, but intimate-use claims should remain cautious and assessment-led.
Treatment fit
Setting: The procedure is carried out in-clinic by a qualified medical professional with specialised intimate health training .
What this means in practice
Setting: The procedure is carried out in-clinic by a qualified medical professional with specialised intimate health training .
Immediate (Days 1-21): Patients often experience early relief from severe dryness due to the highly hydrating nature of the hyaluronic acid frequently mixed with the polynucleotides .
Patient safety
Why diagnosis comes first
Many intimate symptoms overlap. The right treatment depends on whether the issue is GSM, infection, vulval skin disease, scarring, pelvic-floor guarding, medication effect or another cause.
It checks the cause
Up to 85% of anal squamous cell carcinoma survivors and a massive portion of breast cancer survivors suffer from debilitating GSM due to iatrogenic.
It protects safety
Safety Profile: Polynucleotides are formulated as CE-marked Class III medical devices, meaning they lack direct pharmacological activity and possess a strong, established safety profile.
It reviews alternatives
Moisturisers, lubricants, local ooestrogen, pelvic-floor care or specialist review may be more appropriate first.
It sets expectations
Polynucleotides are gradual tissue-support treatments, not instant resolves or promised outcomes.
Non-hormonal does not mean automatic
A hormone-free option may still be unsuitable if there is infection, unexplained bleeding, pregnancy, recent surgery, severe fish allergy or unclear pelvic pain.
Good care explains product source, treatment route, alternatives, limits, aftercare and when another medical pathway is safer.
Considerations
What to consider
Treatment planning should include diagnosis, symptom pattern, allergy risk, medicines, consent, realistic timelines and aftercare.
Consultation priorities
A consultation should review symptoms, medical history, fish allergy, infection risk, bleeding risk, pregnancy status, expectations and alternatives.
Consent
Aftercare
Review
Before treatment
Step 1: Consultation: A detailed review of the patient's symptoms, cancer history, oncology clearance, and the establishment of realistic treatment goals .
During care
Step 2: Procedure Day: Gentle cleansing of the area, application of numbing cream, and the administration of micro-injections of the polynucleotide gel .
Aftercare
Step 3: Immediate Aftercare: Patients can resume normal daily activities, but must strictly avoid sexual intercourse, tampons, hot baths, saunas, and intense exercise for 24 to 72 hours.
When to reassess
If symptoms persist, worsen or do not match expectations, reassessment is safer than repeating treatment automatically.
Practical expectations
Immediate (Days 1-21): Patients often experience early relief from severe dryness due to the highly hydrating nature of the hyaluronic acid frequently mixed with the polynucleotides .
Costs and treatment plans should be confirmed before booking; do not rely on generic package claims.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: hormone-free means automatically safe after cancer
Reality: cancer history still changes suitability and may require specialist advice.
Myth: PN replaces oncology guidance
Reality: oncology or relevant specialist input may be needed before elective intimate treatment.
Myth: all GSM after cancer needs injections
Reality: moisturisers, lubricants, local options and shared decision-making may come first.
Evidence and limits
Mechanism-of-action language should not be treated as proof of a predictable result.
Alternatives still matter
Moisturisers, local hormonal care, pelvic-floor physiotherapy, infection treatment or specialist review may be better for some patients.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting an injectable treatment.
Are red flags absent?
Active infection, unexplained bleeding, severe pain or new vulval changes should be checked first.
Are alternatives clear?
Ask what conservative, hormonal, pelvic-floor or specialist options may be more appropriate.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when diagnosis is clear, goals are realistic, red flags are absent and aftercare is understood.
No red flags
Review plan
Reasons to pause
Pause treatment for active infection, unexplained bleeding, pregnancy, severe fish allergy, recent pelvic surgery, severe pain or changing vulval skin.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Allergy symptoms
Swelling of the lips, tongue or face, breathing difficulty, widespread hives, faintness or collapse needs urgent help.
Bleeding or new skin change
New post-menopausal bleeding, ulcers, changing white plaques, unusual discharge or visible blood in urine should be assessed.
Infection signs
Fever, pus, spreading redness, worsening swelling or feeling unwell after a procedure needs prompt advice.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
Regulatory resources
Authoritative resources
These sources support assessment-led, evidence-aware patient information and help separate clinical care from promotional claims.
NICE menopause recommendations
NICE supports assessment-led discussion of GSM, non-hormonal care and vaginal ooestrogen, including cancer-history nuance.
NHS information on vaginal ooestrogen
NHS patient guidance helps distinguish local vaginal ooestrogen from broader HRT discussions.
ACOG guidance on urogenital symptoms after ooestrogen-dependent breast cancer
This guidance supports shared decision-making and careful framing for cancer survivors with GSM symptoms.
Next step
Book a clinical consultation
A consultation can confirm whether intimate polynucleotides may be suitable, whether another pathway should come first, and what realistic outcomes, risks and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 64 imported records. Additional reviewed material included UK clinical guidance, peer-reviewed clinical papers; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
